Call Us

Hartford:

(860) 527-9020

Manchester:

(860) 646-7704

Cromwell:

(860) 788-6569

Farmington:

(860) 409-7800

Enfield:

(860) 741-4300
We Are Hiring! Careers
Pay Bill
Referrals
Request An Appointment
A newspaper on a wooden desk - Health and Medical

In The News / Media

Home » In The News / Media

Media Highlights

Dr. Tavish Nanda

  • Moderated a national surgical session at the Vit-Buckle Society 2025 on treating simultaneous, bilateral detachments using five cases from the last year he treated in Connecticut. 
  • Provided an invited speaker update for the New England Ophthalmology Society 2025 on Phase 2-3 clinical trials for wet macular degeneration and dry macular degeneration. 
  • Discussed cases of CRUNCH syndrome after anti-VEGF treatment in proliferative diabetic retinopathy, and subsequent surgical management at the Connecticut Society of Eye Physicians 2025 meeting. 
  • Presented an overview of AI in retinal diagnosis at Nantucket Retina 2025. 
  • Taught a nation-wide CME course of novel therapies for geographic atrophy. 
  • Summary of Research Project Findings in 2025: 
    >50% of patients tested for a suspect inherited retinal disorder at Retina Consultants P.C. were found to have a pathogenic gene – including a few cases of serious disorders like oculocutaneous albinism and Krabbe’s Disease – significantly increasing diagnostic yield and physician accuracy. In patients with resistant AMD or DME, Faricimab was found to be superior to high dose Eylea when compared head to head. Endophthalmitis cases referred into the retina practice from injections performed by outside providers were significantly less likely to recover vision compared to those from within the practice, due to referral delays.

Papers

  1. Khodor A, Caranfa J, Nanda T, et al. Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis. Ophthalmology Thereapeutics. 2025 Jul [Online, ahead of print]
  2. Li C, Massa A, Krisch M, Gupta N, Raval N, Nanda T, et al. Utility of screening examination for CMV retinitis among patients with CMV viremia. American Journal of Ophthalmology 2025 May [Online, ahead of print].
  3. Dwomoh E, Patel A, Nanda T (Mentoring Author). Three cases of sterile intraocular inflammation in patients receiving both Faricimab and high-dose Aflibercept in consecutive order. Journal of Vitreoretinal Disease [Accepted, pending print].
  4. Edwards C, Nanda T (Mentoring Author). A rare case of retinal vasculitis in a patient with autoimmune lymphoproliferative syndrome. Ophthalmic Surgery Lasers and Imaging Retina. 2025 Jan;56(1):46-49.
  5. Khodor A, Choi S, Nanda T, et al. Visual and anatomic responses in wet age-related macular degeneration (wAMD) patients with a sub-optimal response to anti-VEGF therapy switched to Faricimab. Journal of Vitreoretinal Disease. 2024 Aug; 8(6):643-650.

Posters

  1. Raymond D, Nanda T (Mentoring Author). Clinical utility and diagnostic relevance of instituting outpatient genetic testing for inherited retinal disease in a high-volume retina practice. European Vitreoretinal Society Nov 2025.
  2. Patel A, Nanda T (Mentoring Author). Real-world incidence and characteristics of sterile intraocular inflammation following intravitreal injection with Faricimab and High Dose Aflibercept. European Vitreoretinal Society Nov 2025.
  3. Phillips C, Nanda T (Mentoring Author). Demographic and statistical characteristics of endophthalmitis at a high-volume community retina practice. New England Ophthalmologic Society (NEOS) May 2025.
  4. Patel A, Nanda T (Mentoring Author). Comparative efficacy of increased anti-VEGF inhibition versus dual anti-VEGF/anti-Ang2 inhibition in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion patients with persistent disease activity. Vit Buckle Society Mar 2025.

Publications

Peer Reviewed Publications

  1. Parikh P, Weiji V, Nanda T (Mentoring Author). Sudden bilateral cataract formation in a young healthy female after simultaneous use of intravenous ketamine and xylazine: a case report. Journal of Cataract & Refractive Surgery Case Reports. 2025 Oct [Online, ahead of print]
  2. Khodor A, Caranfa J, Nanda T, et al. Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis. Ophthalmology Therapeutics. 2025 Jul [Online, ahead of print]
  3. Li C, Massa A, Krisch M, Gupta N, Raval N, Nanda T, et al. Utility of screening examination for CMV retinitis among patients with CMV viremia. American Journal of Ophthalmology 2025 May [Online, ahead of print]. 
  4. Dwomoh E, Patel A, Nanda T (Mentoring Author). Three cases of sterile intraocular inflammation in patients receiving both Faricimab and high-dose Aflibercept in consecutive order. Journal of Vitreoretinal Disease [Accepted, pending print].
  5. Edwards C, Nanda T (Mentoring Author). A rare case of retinal vasculitis in a patient with autoimmune lymphoproliferative syndrome. Ophthalmic Surgery Lasers and Imaging Retina. 2025 Jan;56(1):46-49. 
  6. Khodor A, Choi S, Nanda T, et al. Visual and anatomic responses in wet age-related macular degeneration (wAMD) patients with a sub-optimal response to anti-VEGF therapy switched to Faricimab. Journal of Vitreoretinal Disease. 2024 Aug; 8(6):643-650. 
  7. Nanda T, Chin A, Rifkin L. A 27-year-old female with blurry vision and prolonged light adjustment in the morning. Retina Cases and Brief Reports. 2023 June; 17(4S):S11-S14.
  8. Nanda T, Coombs A, Shi A, Baumal C. Macular findings in X-linked carriers of ocular albinism with a novel GPR143 mutation. Ophthalmic Surgery, Laser, and Retinal Imaging. 2022 Aug;53(8):460-463. 
  9. Tran A, Zhou HW, Nanda T, Godfrey KJ, Tooley AA, North VS, et al. Evolution of asymmetric proptosis during the active phase of thyroid eye disease. Orbit. 2022 June; 42(3):251-255. 
  10. Nanda T, Ross L, Kerr G. A case of brainstem anesthesia after retrobulbar block for globe rupture repair. Case Reports in Anesthesiology. Dec 2021. 
  11. Nanda T, Rasool N, Bearelly S. Tacrolimus induced optic neuropathy in post-lung transplant patients: a series of 3 patients. American Journal of Ophthalmology Case Reports. 2021 Jun 1;22:101056. 
  12. Krawitz B, Sirinek P, Doobin D, Nanda T, Ghiassi M, Liebmann et al. The challenge of managing bilateral acute angle closure glaucoma in the presence of active SARS-Cov-2 infection. Journal of Glaucoma. 2021 Mar 1;30(3):e50-3. 
  13. Nanda T, Chen RWS, Cioffi GA, Liebmann JM. Academia in quarantine. Journal of Glaucoma. 2020 Sept;29(9):723-725.
  14. Nanda T, Bond JB, Chen RWS, Bearelly S, Day R, Cioffi GA, et al. A measured approach to inpatient ophthalmologic screening in the COVID-19 era: a multi-center perspective. Ophthalmology. 2020 Aug 7.
  15. Nanda T, Gong D, Chen RWS, Cioffi GA, DeMoraes G, Glass LRD. The new ophthalmology internship: A trainee curricular survey. Journal of Academic Ophthalmology. 2020 July;12(2):e134-e142.
  16. Nanda T, Breazzano MP, Bearelly S. Clinical utility of pre-transplant ophthalmic consultation for lung transplant recipients: implications in the COVID-19 pandemic era. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2020 Jun 22:1-3.
  17. Nanda T, Sanchez A, Purswani J, Wu CC, Kazim M, Wang TJ. Contour variability in thyroid eye disease with compressive optic neuropathy treated with radiation therapy. Advances in Radiation Oncology. 2020 Feb 29.
  18. Nanda T, Wang A, Ducasse LM, Chen RW, Horowitz J. No-show rates and associated patient factors in an ophthalmology resident practice. Journal of Academic Ophthalmology. 2020 Jan;12(01):e67-73.
  19. Nanda T, Kovach JL. Ophthalmic findings in late stage Sjogren-larsson syndrome. Retinal Cases and Brief Reports. 2019 Jul 1;13(3):251-4.
  20. Nanda T, Tierney P, Blumberg DM. Eye-drop abstinence in glaucoma patients admitted to the hospital service: a single institution assessment. Ophthalmology Glaucoma. 2019 May 1;2(3):188-91.
  21. Smith DR, Bian Y, Wu CC, Saraf A, Tai CH, Nanda T, et al. Natural history, clinical course and predictors of interval time from initial diagnosis to development of subsequent NSCLC brain metastases. Journal of Neuro-oncology. 2019 May 1;143(1):145-55.
  22. Campbell AA, Nanda T, Oropesa S, Kazim M. Age-related changes in the clinical phenotype of compressive optic neuropathy in thyroid eye disease. Ophthalmic Plastic & Reconstructive Surgery. 2019 May 1;35(3):238-42.
  23. Nanda T, Dunbar KE, Campbell AA, Bathras RM, Kazim M. Greater proptosis is not associated with improved compressive optic neuropathy in thyroid eye disease. Ophthalmic Plastic & Reconstructive Surgery. 2018 Jul 1;34(4S):S72-4.
  24. Nanda T, Yaeh A, Wu CC, Jani A, Saad S, Qureshi YH, et al. Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent disease. Journal of Neuro-oncology. 2018 Jan 1;136(2):281-7.
  25. Nanda T, Wu CC, Campbell AA, Bathras RM, Jani A, Kazim M, et al. Risk of dry eye syndrome in patients treated with whole-brain radiotherapy. Medical Dosimetry. 2017 Dec 1;42(4):357-62.
  26. Nanda T, Rasool N, Callahan AB, Stamper RL, Odel JG. Ophthalmic Timolol hallucinations: a case series and review of the literature. Journal of Glaucoma. 2017 Sep 1;26(9):e214-6.
  27. Grubb CS, Jani A, Wu CC, Saad S, Qureshi YH, Nanda T, et al. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery. Journal of Neuro-oncology. 2016 Mar 1;127(1):103-10.
  28. Nanda T. Progressive multifocal leukoencephalopathy in a HIV negative, immunocompetent patient. Case Reports in Neurological Medicine. 2016 Jan 1;2016.
  29. Nanda, T. Grey matter [In: The city of the hospital: on teaching medical students how to write]. Journal of Medical Humanities. 2015, Dec. 36(4): 280-283.
  30. Yaeh A, Nanda T, Jani A, Rozenblat T, Qureshi Y, Saad S, et al. Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. Journal of Neuro-oncology. 2015 Sep 1;124(3):507-14. *Nanda, T and Yaeh A.M. are co-authors.  
  31. Wang TJ, Saad S, Qureshi YH, Jani A, Nanda T, Yaeh AM, et al. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation? Neuro-oncology. 2015 Apr 24;17(7):1022-8.
  32. Jani A, Rozenblat T, Yaeh AM, Nanda T, Saad S, Qureshi YH, et al. The energy index does not affect local control of brain metastases treated by Gamma Knife stereotactic radiosurgery. Neurosurgery. 2015 Mar 31;77(1):119-25.

Non-peer Reviewed Publications/Media

  1. Prasad A, Nanda T. Acute exudative polymorphous vitelliform maculopathy. Jan 2025. 
  2. Nanda T, Shah C. Lens rescue using the double flanged technique. One Network. Sept 2023. 
  3. Nanda T, Alabi R, Warren A. VBS: A focus on fellows. Retina Today. June 2023. 
  4. Nanda T. VBS 2023: Medicolegal Section. Apr 2023. 
  5. Nanda T, Shah C. Floatzillas: Vitreous monsters and the mind. Retina Times. Dec 2022. 
  6. Nanda T, Liang M, Duker J. Optical coherence tomography. In: History of Retina. American Society of Retina Specialists. Sept 2021. 

Submitted Manuscripts/Chapters

  1. Nanda T and Witkin A. Roth Spots. Friedman: Decision Making in Ophthalmology, 1e [Pending Print]
  2. Nanda T and Duker J. Combined Hamartoma of the Retina and RPE. Atlas of Retinal OCT 2nd Edition. [Pending Print]

Oral Presentations

  1. Nanda T. GLP-1 and the Eye. Endocrinology Intercity Grand Rounds Oct 2025. 
  2. Nanda T. AI vs. Grandmaster. Nantucket Retina Jul 2025. 
  3. Nanda T. Surgical Scenarios: “We’re in the west, the west is where you make your own luck.” Vit-Buckle Society Mar 21 2025.
  4. Nanda T. CRUNCH. The impact of anti-VEGF on end-stage disease. Connecticut Society of Eye Physicians Oct 2024. 
  5. Nanda T. Nothing good happens ‘After Hours’. Vit-Buckle Society Apr 2024. 
  6. Nanda T. Monocular Doctor. Vit-Buckle Society Mar 2023. 
  7. Nanda T. Metal on Metal. Vit-Buckle Society Dec 2022.
  8. Nanda T. Switchback vascularity. Yanuzzi Rounds Mar 2022. 
  9. Nanda T. A case of placoid chorioretinitis in a 14-year-old male. Atlantic Coast Retina Club Jan 2022. 
  10. North V, Nanda T, et al. Lacrimal gland enlargement is a risk factor for thyroid eye disease – compressive optic neuropathy. American Society of Ophthalmic Plastic & Reconstructive Surgery Nov 2021. 
  11. Nanda T. Hook, line, and sclera. American Society of Ophthalmic Trauma: Virtual Resident Ophthalmic Trauma Competition Jun 2020. 
  12. Nanda T, et al. A volumetric analysis of spontaneous decompression in thyroid eye disease and compressive optic neuropathy. European Society of Ophthalmic Plastic and Reconstructive Surgery Sept 2019. 
  13. Nanda T, et al. Greater proptosis is not associated with improved compressive optic neuropathy in thyroid eye disease. Oculoplastic and Orbital Surgery: A Lifetime of Care Apr 2019. 
  14. Wang T, Nanda T, et al. Radiation oncology and benign orbital processes. Oculoplastic and Orbital Surgery: A Lifetime of Care Apr 2019. 
  15. Nanda T. A case of sudden bilateral vision loss. Annual Citywide Retina Symposium Aug 2018. 
  16. Campbell AA, Nanda T, et al. Age-related changes in the clinical phenotypes of compressive optic neuropathy in thyroid eye disease. American Society of Ophthalmic Plastic & Reconstructive Surgery Nov 2017. 
  17. Nanda T, et al. The prevalence of clinical asymmetry in a large population of patients with thyroid eye disease and compressive optic neuropathy. Eastern-Atlantic Student Research Forum Feb 2017. 
  18. Nanda T, et al. No significant difference in local control and overall survival between adjuvant stereotactic radiosurgery and salvage stereotactic radiosurgery for brain metastases treated with gross total resection and Gamma Knife radiosurgery. !8th Leksell Gamma Knife Society Meeting May 2016. 

Poster Presentations

  1. Raymond D, Nanda T (Mentoring Author). Clinical utility and diagnostic relevance of instituting outpatient genetic testing for inherited retinal disease in a high-volume retina practice. European Vitreoretinal Society Nov 2025.
  2. Patel A, Nanda T (Mentoring Author). Real-world incidence and characteristics of sterile intraocular inflammation following intravitreal injection with Faricimab and High Dose Aflibercept. European Vitreoretinal Society Nov 2025. 
  3. Phillips C, Nanda T (Mentoring Author). Demographic and statistical characteristics of endophthalmitis at a high-volume community retina practice. New England Ophthalmologic Society (NEOS) May 2025. 
  4. Patel A, Nanda T (Mentoring Author). Comparative efficacy of increased anti-VEGF inhibition versus dual anti-VEGF/anti-Ang2 inhibition in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion patients with persistent disease activity. Vit Buckle Society Mar 2025. 
  5. Khodor A, Caranfa J, Nanda T, et al. Functional and anatomical outcomes of Faricimab in treatment resistant diabetic macular edema (DME): Systemic review and meta-analysis. American Academy of Ophthalmology Oct 2024. 
  6. Lin V, Day R, and Nanda T. Ethnic differences in post operative inflammation after resident performed cataract surgery. American Society of Corneal and Refractive Surgery Apr 2024.
  7. Li C, Nanda T, Srilazmi B. Utility of screening retinal examination in patients with CMV viremia. Vit-Buckle Society Apr 2024.
  8. Nanda T, et al. Visual and anatomic response in wet age-related macular degeneration (wAMD) patients with sub-optimal response to anti-VEGF injections switched to Faricimab. Retina Society Oct 2023. 
  9. Igbinoba Z, Nanda T, et al. Globe displacement ratio as a novel method for improving radiographic accuracy in determining unilateral proptosis in orbital computed tomography imaging. American Society of Neuroradiology Annual Conference May 2021. 
  10. Nanda T, et al.  A novel gaze tracking algorithm as a quantitative index in visual field testing for glaucoma. American Academy of Ophthalmology Annual Conference Nov 2020. 
  11. Nanda T, et al. Brainstem anesthesia following retrobulbar block for globe rupture repair. 73rd Post-Graduate Assembly in Anesthesia Dec 2019. 
  12. Nanda T, et al. An assessment of radiation treatment planning in thyroid eye disease and compressive optic neuropathy. American Society of Ophthalmic Plastic & Reconstructive Surgery Oct 2019. 
  13. Nanda T, et al. Lacrimal gland size is associated with fat volume expansion in thyroid eye disease and compressive optic neuropathy. American Society of Ophthalmic Plastic & Reconstructive Surgery Oct 2019.
  14. Nanda T, et al. Incongruous improvement in acquired dyschromatopsia and visual field changes in thyroid eye disease-compressive optic neuropathy treated with radiotherapy. European Society of Ophthalmic Plastic and Reconstructive Surgery Sept 2019. 
  15. Nanda T, et al. Follow-up trends in a resident clinic: a Medicare/Medicaid population analysis. The Association for Research in Vision and Ophthalmology Apr 2019. 
  16. Nanda T, et al. Pattern standard deviation in thyroid eye disease and compressive optic neuropathy (TED-CON). North American Neuro-Ophthalmology Society Mar 2019. 
  17. Nanda T, et al. Electroencephalogram (EEG) eyeblink artifact as a clinical measurement in Parkinsons patients. North American Neuro-Ophthalmology Society Mar 2019.
  18. Nanda T, et al. Eye-drop abstinence in glaucoma patients admitted to an inpatient hospital service: a single institution experience. American Glaucoma Society Mar 2019. 
  19. Nanda T, et al. Representation of intra-orbital disease burden by Hertel exophthalmometry vs. globe displacement in thyroid eye disease and compressive optic neuropathy. International Thyroid Eye Disease Symposium Feb 2019. 
  20. Nanda T, et al. Prevalence of clinical and volumetric asymmetry in a large population of patients with bilateral thyroid eye disease and compressive optic neuropathy. International Thyroid Eye Disease Symposium Feb 2019.
  21. Nanda T, et al. Non-linear visual field improvement in thyroid eye disease and compressive optic neuropathy: a radiation rebound effect? American Society of Ophthalmic Plastic & Reconstructive Surgery Oct 2018. 
  22. Nanda T, et al. Heterogeneity of treatment effect: radiation therapy for Graves orbitopathy and compressive optic neuropathy. American Society of Radiation Oncology Oct 2018. 
  23. Nanda T, et al. Does exophthalmos protect against compressive disease? A clinical and anatomic investigation. American Society of Ophthalmic Plastic & Reconstructive Surgery Nov 2017. 
  24. Bian Y, Wu CC, Tai CH, Saraf A, Andrews JL, Lapa ME, Nanda T, et al. Risk factors associated with interval time between initial non-small cell lung cancer (NSCLC) diagnosis and development of brain metastases. American Society of Radiation Oncology Sept 2017. 
  25. Nanda T, et al. Larger lacrimal gland size associated with clinical symptomology in patients with thyroid eye disease and compressive optic neuropathy. Association for Research in Vision and Ophthalmology May 2017. 
  26. Dunbar K, Nanda T, et al. Thyroid eye disease – compressive optic neuropathy is not inversely associated with exophthalmos. Association for Research in Vision and Ophthalmology May 2017.
  27. Nanda T, et al. The risk of dry eye syndrome (DES) in patients treated with whole brain radiotherapy. American Society of Ophthalmic Plastic & Reconstructive Surgery Oct 2016. 
  28. Saadatmand H, Nanda T, et al. Secondary malignancy rates and adverse radiation effects after stereotactic radiosurgery for benign acoustic neuroma: an institutional experience. Society for Neuro-Oncology Sept 2016. 
  29. Yaeh AM, Nanda T, et al. Adjuvant stereotactic radiosurgery to the tumor bed improves local control and progression free survival following gross total resection of brain metastases. American Society of Radiation Oncology Oct 2015. 
  30. Yaeh AM, Nanda T, et al. Control of brain metastases from radioresistant tumors treated by Gamma Knife radiosurgery. Society of Neuro-Oncology Nov 2014. 
  31. Saad S, Wang TJ, Jani A, Qureshi YH, Yaeh A, Nanda T, et al. Number of brain metastases influences survival following gamma knife radiosurgery. Society of Neuro-Oncology Nov 2014. 
  32. Nanda T, et al. Cultural differences in behavior and psychophysiological emphatic reactions to physical pain. 13th Annual Undergraduate Symposium for Scholarly and Creative Work Apr 2011. 

Teaching/Grand Rounds

  1. A New Era in Geographic Atrophy: Addressing the Complement System and Improving Patient Outcomes. June-Aug 2025.
  2. Eyes on Excellence. Connecticut Society of Medical Assistants. April 2025. 
  3. Challenges of Managing Diabetic Eye Disease. In Focus: Evolve Medical CME. Oct 2024. 
  4. Understanding Age Related Macular Degeneration. Hartford Hospital Community Education Series. Jan 2023. 
  5. Syfovre, Izervay, and the Geographic Atrophy Resolution: Picking the Right Patient. Optometry Education Series. Oct 2023.
  6. Private Equity in Ophthalmology. MSEPS Young Ophthalmologist Committee. Sept 2023. 
  7. Visual and anatomic response in wet age-related macular degeneration (wAMD) patients with a sub-optimal response to anti-VEGF injections switched to Faricimab Jun 2023. 
  8. Chronic Myeloid Leukemia: Grand Rounds. New England Eye Center, Boston MA, Mar 2022. 
  9. Diabetic Retinopathy: Resident Education Series. New England Eye Center, Boston MA, Jan 2022.
  10. Retina Imaging Rounds. Ophthalmic Consultants of Boston, Boston MA, Oct 2021, Nov 2021. 
  11. Duker Imaging Rounds. New England Eye Center, Boston MA, Sept 2021, Feb 2022.
  12. Mystery Case: Bilateral CRAO. Grand Rounds. Edward S. Harkness Eye Institute, New York NY, Jan 2021
  13. Under the See: A case of scuba-diving retinopathy. Grand Rounds. Edward S. Harkness Eye Institute, New York NY, Feb 2020. 
  14. A Review of Ophthalmic Consultation: CMV retinitis/lung transplant evaluation. Edward S. Harkness Eye Institute, New York NY, Sept 2019.  
  15. Interesting Cases in Neuro-Radiology: The orbit. Edward S. Harkness Eye Institute, New York NY, Mar 2019.
  16. Cases in Ocular Oncology: Idiopathic sclerosing orbital inflammation. Grand Rounds. Edward S. Harkness Eye Institute, New York NY, Feb 2019.

Dr. Scott Walter

  • Sept 2025 – presented “Expert Consensus on the Relative Importance of Clinical Risk Factors for Malignancy of Melanocytic Choroidal Lesions” at Retina Society in Chicago, IL
  • July 2025 – Retina Atlas Chapter of the Year Award, American Society of Retina Specialists
  • May 2025 – presented “A case-based approach to using Vabysmo®”. Product theater (on behalf of Genentech) at the 23rd Duke Advanced Vitreous Surgery course, Durham NC
  • March 2025 – presented “Virtual and AI scribing in retina: Current and future trends in clinical documentation for the retina specialist.” 26th annual ASRS Business of Retina meeting, Atlanta GA
  • March 2025 – participated as a panelist in “Medical Retina Rapid Fire Panel”. 13th annual Vit-Buckle Society meeting, Austin TX
  • March 2025 – participated in Biosimilar debate: “Anti-VEGF biosimilars are not preferred over their reference products”. 799th New England Ophthalmological Society (NEOS) meeting, Boston MA
  • Feb 2025 – presented “Current practice patterns in evaluation and management of small tumors: Results of the COOG survey”; and served on Ocular oncologist panel: GPS-guided management of UMTIMPs; at Collaborative Ocular Oncology Group annual meeting, Dallas TX
  • Nov 2024 – presented “Lessons learned from my coolest uveitis cases.”; and “Management of patients with GA: A case-based expert discussion”. (Product theater on behalf of Apellis); and moderated Uveitis Case Conference at OSN New York Retina meeting, New York NY
  • October 2024 – “Advanced therapy for retinal vascular diseases: Enhancing durability and reducing treatment burden.” Grand rounds (presented on behalf of Ophthalmology Times) at the American Academy of Ophthalmology meeting, Chicago IL
  • Sept 2024 – Inducted into the Retina Society and presented “Photodynamic therapy in ocular oncology.” At the 57th annual meeting of the Retina Society, Lisbon, Portugal 

Presentations

  1. Sept 2025 – presented “Expert Consensus on the Relative Importance of Clinical Risk Factors for Malignancy of Melanocytic Choroidal Lesions” at Retina Society in Chicago, IL
  2. July 2025 – Retina Atlas Chapter of the Year Award, American Society of Retina Specialists
  3. May 2025 – presented “A case-based approach to using Vabysmo®”. Product theater (on behalf of Genentech) at the 23rd Duke Advanced Vitreous Surgery course, Durham NC
  4. March 2025 – presented “Virtual and AI scribing in retina: Current and future trends in clinical documentation for the retina specialist.” 26th annual ASRS Business of Retina meeting, Atlanta GA
  5. March 2025 – participated as a panelist in “Medical Retina Rapid Fire Panel”. 13th annual Vit-Buckle Society meeting, Austin TX
  6. March 2025 – participated in Biosimilar debate: “Anti-VEGF biosimilars are not preferred over their reference products”. 799th New England Ophthalmological Society (NEOS) meeting, Boston MA
  7. Feb 2025 – presented “Current practice patterns in evaluation and management of small tumors: Results of the COOG survey”; and served on Ocular oncologist panel: GPS-guided management of UMTIMPs; at Collaborative Ocular Oncology Group annual meeting, Dallas TX
  8. Nov 2024 – presented “Lessons learned from my coolest uveitis cases.”; and “Management of patients with GA: A case-based expert discussion”. (Product theater on behalf of Apellis); and moderated Uveitis Case Conference at OSN New York Retina meeting, New York NY
  9. October 2024 – “Advanced therapy for retinal vascular diseases: Enhancing durability and reducing treatment burden.” Grand rounds (presented on behalf of Ophthalmology Times) at the American Academy of Ophthalmology meeting, Chicago IL
  10. Sept 2024 – Inducted into the Retina Society and presented “Photodynamic therapy in ocular oncology.” At the 57th annual meeting of the Retina Society, Lisbon, Portugal 

Publications

  1. Song W, Randawa S, Johnson MW, … Walter SD, … Sarraf D. Multifocal vitelliform paravascular retinopathy (MVPR): A new disorder in the vitelliform spectrum. Am J Ophthalmol. 2025;269:362-72.
  2. Dollar JD, Decatur CL, Weis E, … Walter SD, … Harbour JW. Early genetic evolution of driver mutations in uveal melanoma. [Preprint in medRxiv]. 2025: 06.10.25329358.
  3. Harbour JW, Correa ZM, Shefler AC, … Walter SD, … Zhang S. 15-Gene Expression Profile and PRAME as integrated prognostic test for uveal melanoma: First report of the Collaborative Ocular Oncology Group study no. 2. J. Clin Oncol. 2024;42(28):3319-29.

Affiliations & Memberships

Hartford HealthCare
UCONN School of Medicine
Connecticut Children Medical Centre
Trinity Health Of New England
Eastern Connecticut Health Network
Quinnipiac University

Awards and Recognitions

Top U.S. News Doctor
Best Doctors
Castle Cannoly
Consumers' Research Council of America (CRCA)

Success Stories

Read More Stories